Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients

J. T. McCarthy, D. S. Milliner, D. F. Schmidt, B. J. Schniepp, S. B. Kurtz, W. J. Johnson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We studied the in vitro and in vivo characteristics of aluminium (Al) removal by coated charcoal hemoperfusion (HP) in combination with intravenous deferoxamine (DFO). DFO enhanced the clearance of Al by HP in vitro after 180 minutes of perfusion with a solution containing 403.3 ± 14.0 ng/ml of Al at 150 ml/min. The Al clearance was 139 ± 1.0 ml/min with DFO and 49 ± 10.0 ml/min (P < 0.001) without DFO. Addition of DFO enhanced in vitro Al removal from 5.5 ± 0.9 mg to 10.0 ± 1.2 mg (P < 0.05). During our in vivo studies, an HP device was in series in the dialysis circuit after a Cuprophan hemodialyzer. Eight patients with Al toxicity were studied on twelve occasions. Patients received DFO (40 mg/kg) 40 hours before the study. The total Al clearance with the combined hemodialysis (HD) and HP devices was higher than that obtained by the dialyzer alone at 30 minutes (62 ± 4.9 ml/min vs. 25 ± 2.5 ml/min, P < 0.02) and after 180 to 210 minutes (32 ± 3.0 ml/min vs. 19 ± 2.9 ml/min, P < 0.02). After 120 minutes the Al clearance by the HP device alone was significantly lower than the initial Al clearance by HP. Combined HD plus HP removed 2.9 ± 0.4 mg of Al, whereas the total removal of Al by HD alone was 1.5 ± 0.3 mg (P < 0.01).

Original languageEnglish (US)
Pages (from-to)804-808
Number of pages5
JournalKidney International
Volume34
Issue number6
StatePublished - 1988

Fingerprint

Hemoperfusion
Deferoxamine
Charcoal
Aluminum
Dialysis
Renal Dialysis
Equipment and Supplies
Artificial Kidneys
Perfusion

ASJC Scopus subject areas

  • Nephrology

Cite this

McCarthy, J. T., Milliner, D. S., Schmidt, D. F., Schniepp, B. J., Kurtz, S. B., & Johnson, W. J. (1988). Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients. Kidney International, 34(6), 804-808.

Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients. / McCarthy, J. T.; Milliner, D. S.; Schmidt, D. F.; Schniepp, B. J.; Kurtz, S. B.; Johnson, W. J.

In: Kidney International, Vol. 34, No. 6, 1988, p. 804-808.

Research output: Contribution to journalArticle

McCarthy, JT, Milliner, DS, Schmidt, DF, Schniepp, BJ, Kurtz, SB & Johnson, WJ 1988, 'Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients', Kidney International, vol. 34, no. 6, pp. 804-808.
McCarthy JT, Milliner DS, Schmidt DF, Schniepp BJ, Kurtz SB, Johnson WJ. Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients. Kidney International. 1988;34(6):804-808.
McCarthy, J. T. ; Milliner, D. S. ; Schmidt, D. F. ; Schniepp, B. J. ; Kurtz, S. B. ; Johnson, W. J. / Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients. In: Kidney International. 1988 ; Vol. 34, No. 6. pp. 804-808.
@article{64dede85ecf74e72923a735b901aee0c,
title = "Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients",
abstract = "We studied the in vitro and in vivo characteristics of aluminium (Al) removal by coated charcoal hemoperfusion (HP) in combination with intravenous deferoxamine (DFO). DFO enhanced the clearance of Al by HP in vitro after 180 minutes of perfusion with a solution containing 403.3 ± 14.0 ng/ml of Al at 150 ml/min. The Al clearance was 139 ± 1.0 ml/min with DFO and 49 ± 10.0 ml/min (P < 0.001) without DFO. Addition of DFO enhanced in vitro Al removal from 5.5 ± 0.9 mg to 10.0 ± 1.2 mg (P < 0.05). During our in vivo studies, an HP device was in series in the dialysis circuit after a Cuprophan hemodialyzer. Eight patients with Al toxicity were studied on twelve occasions. Patients received DFO (40 mg/kg) 40 hours before the study. The total Al clearance with the combined hemodialysis (HD) and HP devices was higher than that obtained by the dialyzer alone at 30 minutes (62 ± 4.9 ml/min vs. 25 ± 2.5 ml/min, P < 0.02) and after 180 to 210 minutes (32 ± 3.0 ml/min vs. 19 ± 2.9 ml/min, P < 0.02). After 120 minutes the Al clearance by the HP device alone was significantly lower than the initial Al clearance by HP. Combined HD plus HP removed 2.9 ± 0.4 mg of Al, whereas the total removal of Al by HD alone was 1.5 ± 0.3 mg (P < 0.01).",
author = "McCarthy, {J. T.} and Milliner, {D. S.} and Schmidt, {D. F.} and Schniepp, {B. J.} and Kurtz, {S. B.} and Johnson, {W. J.}",
year = "1988",
language = "English (US)",
volume = "34",
pages = "804--808",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Deferoxamine and coated charcoal hemoperfusion to remove aluminium in dialysis patients

AU - McCarthy, J. T.

AU - Milliner, D. S.

AU - Schmidt, D. F.

AU - Schniepp, B. J.

AU - Kurtz, S. B.

AU - Johnson, W. J.

PY - 1988

Y1 - 1988

N2 - We studied the in vitro and in vivo characteristics of aluminium (Al) removal by coated charcoal hemoperfusion (HP) in combination with intravenous deferoxamine (DFO). DFO enhanced the clearance of Al by HP in vitro after 180 minutes of perfusion with a solution containing 403.3 ± 14.0 ng/ml of Al at 150 ml/min. The Al clearance was 139 ± 1.0 ml/min with DFO and 49 ± 10.0 ml/min (P < 0.001) without DFO. Addition of DFO enhanced in vitro Al removal from 5.5 ± 0.9 mg to 10.0 ± 1.2 mg (P < 0.05). During our in vivo studies, an HP device was in series in the dialysis circuit after a Cuprophan hemodialyzer. Eight patients with Al toxicity were studied on twelve occasions. Patients received DFO (40 mg/kg) 40 hours before the study. The total Al clearance with the combined hemodialysis (HD) and HP devices was higher than that obtained by the dialyzer alone at 30 minutes (62 ± 4.9 ml/min vs. 25 ± 2.5 ml/min, P < 0.02) and after 180 to 210 minutes (32 ± 3.0 ml/min vs. 19 ± 2.9 ml/min, P < 0.02). After 120 minutes the Al clearance by the HP device alone was significantly lower than the initial Al clearance by HP. Combined HD plus HP removed 2.9 ± 0.4 mg of Al, whereas the total removal of Al by HD alone was 1.5 ± 0.3 mg (P < 0.01).

AB - We studied the in vitro and in vivo characteristics of aluminium (Al) removal by coated charcoal hemoperfusion (HP) in combination with intravenous deferoxamine (DFO). DFO enhanced the clearance of Al by HP in vitro after 180 minutes of perfusion with a solution containing 403.3 ± 14.0 ng/ml of Al at 150 ml/min. The Al clearance was 139 ± 1.0 ml/min with DFO and 49 ± 10.0 ml/min (P < 0.001) without DFO. Addition of DFO enhanced in vitro Al removal from 5.5 ± 0.9 mg to 10.0 ± 1.2 mg (P < 0.05). During our in vivo studies, an HP device was in series in the dialysis circuit after a Cuprophan hemodialyzer. Eight patients with Al toxicity were studied on twelve occasions. Patients received DFO (40 mg/kg) 40 hours before the study. The total Al clearance with the combined hemodialysis (HD) and HP devices was higher than that obtained by the dialyzer alone at 30 minutes (62 ± 4.9 ml/min vs. 25 ± 2.5 ml/min, P < 0.02) and after 180 to 210 minutes (32 ± 3.0 ml/min vs. 19 ± 2.9 ml/min, P < 0.02). After 120 minutes the Al clearance by the HP device alone was significantly lower than the initial Al clearance by HP. Combined HD plus HP removed 2.9 ± 0.4 mg of Al, whereas the total removal of Al by HD alone was 1.5 ± 0.3 mg (P < 0.01).

UR - http://www.scopus.com/inward/record.url?scp=0024206584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024206584&partnerID=8YFLogxK

M3 - Article

C2 - 3210542

AN - SCOPUS:0024206584

VL - 34

SP - 804

EP - 808

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -